DSK 2026 Q1: Consolidated Revenue Up, Loss Narrowed, Change of Control on Track

2026 Q1 consolidated revenue: 49.0bn won (+58% YoY), operating loss: 5.72bn won, net loss attributable to parent: 2.38bn won (improved from 3.75bn won in Q1 2025)
Subsidiary PROTOX obtained domestic product approval for botulinum toxin 'Protoxin' in Nov 2025, expected to contribute to sales
Credit rating downgraded: BBB (May 2025) → BBB- (Apr 2026) by NICE D&B
Change of control transaction ongoing: balance of 70.65bn won to be paid by Jun 15, 2026, and EGM on Jun 30 to appoint new directors
Borrowings: 23.0bn won (current), cash and cash equivalents: 23.7bn won, equity: 112.9bn won
No dividends or share buybacks
One pending lawsuit (amount: 27.8mn won)